An interventional study of BMT4me 2.0 app in Stem Cell Transplant, Adherence, Medication and Digital Health, sponsored by Micah Skeens. Completed at 1 site in United States. Open to participants aged 0 Years to 21 Years. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Micah Skeens · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 463 studies in Medication Adherence with a site in United States — 59 open to participants now, 74 under way, 1 of them phase 3. Medication Adherence · United States.
Among the 463 studies in Medication Adherence with a site in United States, this one is the 286th largest by enrollment of the 422 interventional ones that give a count, is one of 28 that started in 2022, is one of 368 with no phase, and was the 373rd registered.
943 studies on the registry are indexed under Medication Adherence; 162 are open to participants now.
Browse Medication Adherence studies →59 of the 463 studies in Medication Adherence with a site in United States are open now. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 18+
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 15–24
Children's Hospital Los Angeles · Sites in United States
Ages 10–17
Northwestern University · Sites in United States
Ages 60+
University of Oklahoma · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 81 Medication Adherence studies recruiting now, 52 (64%) set no upper age limit and 21 (26%) stop at 75 or younger; 15 take children under 18; 12 take healthy volunteers.
This study: 0 Years to 21 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
463 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 16 · Phase 3 12 · Phase 4 13
First in 1993; this study’s year is marked. 28 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is below the median of 120 across 773 interventional studies indexed under Medication Adherence.
Median enrollment 96 across the 422 interventional studies, 140 across the 41 observational. Of the 359 that completed or were terminated, 138 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 463 have an industry lead sponsor. The 10 most frequent:
Micah Skeens is the lead sponsor of 2 studies on the registry; none are open to participants now.
Micah Skeens has 1 study filed under Medication Adherence — fewer than ten, so there is no comparison to draw.
39 of the studies in Medication Adherence with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06550804Phase 3University of Illinois at ChicagoTesting a Real-time Electronic Antiretroviral Adherence Monitoring Intervention | 2027-03 |
| NCT05997914University of Massachusetts, WorcesterStorytelling for Reducing Gap in Anticoagulation Use in African Americans With Atrial Fibrillation | 2026-11 |
| NCT04997499Tufts Medical CenterAdolescent Subcutaneous (SQ) Injection Video Validation | 2026-12 |
| NCT06865755San Diego State UniversityCollaborative Research: Multiscale Modeling and Intervention for Improving Long-Term Medication | 2026-12 |
| NCT07943663nucleusRx IncDevelopment of a Virtual Health Care Platform in Heart Failure Patients Transitioning From Hospital to Home | 2026-12-10 |
Add all 39 to your calendar (.ics) → With an account.
Among the 463 studies in Medication Adherence with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a mixed methods, prospective longitudinal pilot RCT to evaluate the 1) acceptability of a newly developed mHealth app (BMT4me), 2) the feasibility of enrolling and retaining caregivers of children in the acute phase post-HSCT, and 3) the potential efficacy of an mHealth app on adherence to immunosuppressants in post-HSCT children discharged during the acute phase.
In the United States, poor adherence accounts for up to 70% of all medication-related hospital admissions, resulting in $100 billion in healthcare costs annually Adherence rates have been reported as low as 0% in pediatric patients. Reasons for non-adherence are multifactorial. The most important determinants of non-adherence are consistently documented as complexity and duration of treatment regimens, as well as forgetfulness. Thus, children undergoing difficult hematopoietic stem cell transplants (HSCT) that require medication indefinitely are at high risk for medication non-adherence.
Only 4 published studies exist regarding adherence in pediatric HSCT. None address adherence to immunosuppressant medication, nor are they RCTs. Second, the complexity of most interventions for adherence is counter to the geographic, resource, and time constraints families of chronically ill children face. Adherence interventions based on conventional behavior theory have been cumbersome for families already stressed due to chronic illness. BE design is a significant paradigm shift to a simpler, less onerous approach that can engage those patients and families that would otherwise forego complicated adherence interventions. Although mHealth adherence apps are a widely available, simple, and innovative approach to addressing these problems, a third gap relates to poor usability. For example, a recent review of pediatric adherence apps found that none identified individual barriers to adherence, and nearly all were designed for adults. Thus, there is an urgent need to develop and evaluate innovative, accessible, and evidence-based approached to adherence among children receiving HSCT to prevent morbidity and mortality from GVHD.
The impact of non-adherence on clinical outcomes is largely unknown in pediatric HSCT. poor adherence is generally associated with adverse outcomes, including complications, hospital admissions, and even death. The societal burden of cancer care and HSCT is substantial and likely to increase based on the growing number of transplants each year. Clinicians and researchers have focused on GVHD prevention to minimize unnecessary treatment-related deaths. Acute GVHD develops in the first 100 days post-transplant. Children that develop acute GVHD have a 30% to 50% chance of survival. Morbidity and mortality due to GVHD can be decreased through prophylactic use of immunosuppressants. Although these medications are costly and produce unpleasant side effects, adherence is critical to decrease complications, reduce readmissions, and ultimately increase quality of life and survival.
Adherence is complex, but ultimately, the final common pathway to adherence is human behavior. In pediatrics, adherence is largely dependent on parents. As the primary caregivers, they are responsible for ensuring children receive the prescribed therapy correctly. In a high-risk HSCT population, caregivers are isolated with their child due to infection risk and must manage challenging treatment regimens at home, often with limited time and support. Complex behavioral interventions, typically employed to address adherence, are difficult to deliver and manage in the context of these daily tasks. Alternatively, behavioral economics (BE) theory suggests that small "nudges" can produce and sustain behavior change. A BE approach is a significant paradigm shift and assumes decision-making can be influenced through low-intensity interventions to lead patients to optimal choices. Improved adherence to medication and exercise programs using BE designed interventions in adults have been positive. Within pediatrics, BE has been successful in reducing childhood obesity, increasing vaccination rates, and improving adherence rates to infant HIV medications.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The intervention group will be receiving the BMT4me 2.0 app at discharge as the primary intervention.
Device: BMT4me 2.0 app
The control group will be receiving usual care at discharge. These participants will not be receiving the BMT4me 2.0 app.
The BMT4me app was designed by AWRI RISI developers and has been through multiple phases of stakeholder testing. The app is a virtual assistant for caregivers, allowing for medication record keeping, medication and refill reminders, symptom tracking, and a word and picture journal. All data is secured on the individuals password protected phone.
Momentary Event Monitoring System (MEMS) Caps
MEMS Caps collect daily data via a micro-electronic circuit that registers the opening and closing of the threaded pill bottle. Each opening and closing is assumed to reflect an administered and consumed medication dose. This data will be collected either at weekly or monthly from participants at their visits in the BMT clinic as a direct measure of adherence. Electronic monitors contain micro-electronic circuits that date and time-stamp each time the container is opened to remove a dose of medication. Data from the electronic monitors will be downloaded using cloud or computer-based software, at each study visit.53,54 An adherence percentage was calculated by dividing the number of doses taken by the number of doses prescribed for each day. All of the electronic monitors have been independently tested for accuracy.55
Time frame: Baseline to day 100
Medication Adherence Measure (MAM)
The MAM is semi-structured interview specific to pediatrics, conducted with the parent, to obtain an individual score in each module. The score is represented in percentages of the number of required doses. A total summary score can be calculated across all medications, as well as separately. This allows for quantification of the degree of adherence on a continuum.
Time frame: Baseline to day 100
System Usability Scale
The SUS is a 10-item questionnaire routinely used to evaluate the functionality and acceptability of mHealth apps. Items are rated on a 5-point scale and scores range from 0 to 100. A higher score indicates better usability. Reliability and validity have been well established. A score of \> 68% is considered above average.
Time frame: Exit (Day 100)
Posttransplant Perception Survey
The posttransplant perception survey is a self-report clinical assessment tool adapted from the kidney transplant population for this trial. The tool contains 7 questions asking participants to report on their views about their child's health and perceptions post-transplant. Questions are rated on a 5-point Likert scale. The first three questions related to worry about child's health and are considered the "Worry" subscale which ranges from 3 to 15, with higher scores indicating more worry. The second four questions relate to the understanding of child's health and are considered the "Understanding" subscale. Scores range from 4 to 20, where higher scores indicate less understanding.
Time frame: Baseline (Week 0) to 100 Days Post Transplant
Barrier Assessment Tool
The Barrier Assessment Tool (BAT) is a self-report clinical assessment tool. The tool contains 14 commonly endorsed barriers with a checkbox next to each item. Domains include logistical issues (e.g., forgetting, inconvenience), ingestion difficulties (e.g., swallowing, taste), efficacy (e.g., feel I don't need it), financial difficulties, regimen characteristics (e.g., too many medications, side effects), and patient-specific issues (e.g., refusal by child, embarrassment). A sum total of the number of barriers is calculated, as well as concordance between caregiver and patient report. In the feasibility study, the average concordance between caregiver and patient report of each barrier (n=48) was 0.299.53 The total barrier score will be used. A sum total of 0 to 14 could be calculated, with higher scores indicating more barriers.
Time frame: Baseline (Week 0) to 100 Days Post Transplant
Caregiver Satisfaction
Satisfaction will be assessed via semi-structured interviews and an electronic version of the Caregiver Satisfaction Questionnaire with caregivers. Caregivers will be asked for feedback regarding participation in the intervention, benefit, burden, barriers, suggested modifications, and overall satisfaction. Suggested modifications to the app and advice to the healthcare team will also be solicited. Due to the qualitative nature of the interview, caregiver responses cannot be scored but will be coded for themes. Nine questions are included on the Caregiver Satisfaction Questionnaire and responses are on a 1 to 4 Likert scale. A total sum score ranges from 9 to 36, with higher scores indicating more satisfaction.
Time frame: Exit (Day 100)
Pediatric Quality of Life Inventory (PedsQL) Version 4.0
Caregivers completed the Pediatric Quality of Life Inventory (PedsQL) every three weeks (at week 3, week 6, and week 9). The PedsQL has 4 domains related to physical, emotional, social, and school functioning totaling 23 items. Items are rated on a 3 or 5-point Likert scale. All items (23) are summed to a total PedsQL score. Total scores range from 0 - 100, with higher scores indicating higher quality of life. Versions are based on child age: (a) 5-7, (b) 8-12 and, (c) 13-18 years old.
Time frame: Week 3, Week 6, and Week 9
Medy Remote Patient Management (RPM) Medication Box by Vaica
Medy RPM collects daily data via an NFC reader. Each opening and closing is assumed to reflect an administered and consumed medication dose. This data will be collected monthly from participants as a direct measure of adherence. Electronic monitors contain micro-electronic circuits that date and time-stamp each time the container is opened to remove a dose of medication. Data from the electronic monitors will be downloaded using cloud or computer-based software, at each study visit. An adherence percentage was calculated by dividing the number of doses taken by the number of doses prescribed for each day. All of the electronic monitors have been independently tested for accuracy.
Time frame: Baseline to day 100
Wisepill
Wisepill is a pillbox that collects data on medication usage through the internet. The Wisepill model utilized was evriMED1000. This data was collected as a direct measure of adherence. The evriMED1000 pillbox recorded when the lid was opened and closed and uploaded data in real time into a cloud-based server, where data was retrieved after study exit.
Time frame: Baseline to day 100
Medication Level Variability Index (MLVI)
Medication Level Variability Index (MLVI) measures the variation of tacrolimus levels in the blood of a patient over time. Higher variability has been associated with increased risk of poor outcomes following solid organ transplant, with limited findings suggesting a similar trend in HCT. MLVI is calculated using the standard deviation of three or more medication levels. The range of scores is not consistent, but MLVI typically falls between 0-10, with higher scores indicating higher variability (and therefore higher risk of complications). There are clinically significant cutoff scores for solid organ transplant populations; an MLVI of 3 or higher is generally considered to be a high risk. Both continuous and dichotomous scores were used in this analysis.
Time frame: Weekly until day 100
Number of Participants With Graft vs. Host Disease (GVHD)
GVHD will be assessed on the international standard acute GVHD grading and staging scale. Provider grading will be per organ system on a 1-4 scale, with an overall score given weekly.
Time frame: Weekly until day 100
Number of Participants With Readmissions
Readmission rates will be determined by the number of admissions requiring greater than a 24-hour stay within the first 100 days after discharge. Reason for readmission will be recorded and based on the EMR discharge diagnosis. In addition, a sub-analysis of readmissions within the first 30 days after initial discharge post-HSCT will be completed.
Time frame: Weekly until day 100
Caregiver Education Level
Caregiver reported education level
Time frame: Baseline (Week 0)
Annual Household Income
Caregiver reported annual household income
Time frame: Baseline (Week 0)
Participants were approached in-person at inpatient rooms post BMT, prior to discharge. One participant was recruited per family, either the caregivers themselves or the adolescent who self-managed their medication. We refer to all participants as caregivers.
| Milestone | BMT4me 2.0 Intervention Group | BMT4me 2.0 Control Group |
|---|---|---|
| Started | 24 | 26 |
| Completed | 22 | 23 |
| Not completed | 2 | 3 |
MEMS Caps collect daily data via a micro-electronic circuit that registers the opening and closing of the threaded pill bottle. Each opening and closing is assumed to reflect an administered and consumed medication dose. This data will be collected either at weekly or monthly from participants at their visits in the BMT clinic as a direct measure of adherence. Electronic monitors contain micro-electronic circuits that date and time-stamp each time the container is opened to remove a dose of medication. Data from the electronic monitors will be downloaded using cloud or computer-based software, at each study visit.53,54 An adherence percentage was calculated by dividing the number of doses taken by the number of doses prescribed for each day. All of the electronic monitors have been independently tested for accuracy.55
| Percent | BMT4me 2.0 Intervention Group | BMT4me 2.0 Control Group |
|---|---|---|
| Momentary Event Monitoring System (MEMS) Caps | 62.78 ± 22.14 | 61.06 ± 32.92 |
The MAM is semi-structured interview specific to pediatrics, conducted with the parent, to obtain an individual score in each module. The score is represented in percentages of the number of required doses. A total summary score can be calculated across all medications, as well as separately. This allows for quantification of the degree of adherence on a continuum.
| Percent | BMT4me 2.0 Intervention Group | BMT4me 2.0 Control Group |
|---|---|---|
| Medication Adherence Measure (MAM) | 99.25 ± 1.55 | 98.52 ± 2.62 |
The SUS is a 10-item questionnaire routinely used to evaluate the functionality and acceptability of mHealth apps. Items are rated on a 5-point scale and scores range from 0 to 100. A higher score indicates better usability. Reliability and validity have been well established. A score of \> 68% is considered above average.
| Scores on a scale | BMT4me 2.0 Intervention Group |
|---|---|
| System Usability Scale | 70.00 ± 15.08 |
The posttransplant perception survey is a self-report clinical assessment tool adapted from the kidney transplant population for this trial. The tool contains 7 questions asking participants to report on their views about their child's health and perceptions post-transplant. Questions are rated on a 5-point Likert scale. The first three questions related to worry about child's health and are considered the "Worry" subscale which ranges from 3 to 15, with higher scores indicating more worry. The second four questions relate to the understanding of child's health and are considered the "Understanding" subscale. Scores range from 4 to 20, where higher scores indicate less understanding.
| Scores on a scale | BMT4me 2.0 Intervention Group | BMT4me 2.0 Control Group |
|---|---|---|
| Worry Subscale Enrollment (Week 0) | 8.21 ± 3.12 | 8.27 ± 2.20 |
| Understanding Subscale Enrollment (Week 0) | 5.46 ± 2.32 | 5.73 ± 2.07 |
| Worry Subscale Exit (100 Days Post Transplant) | 7.38 ± 2.42 | 6.78 ± 3.01 |
| Understanding Subscale Exit (100 Days Post Transplant) | 6.05 ± 1.94 | 5.52 ± 2.13 |
The Barrier Assessment Tool (BAT) is a self-report clinical assessment tool. The tool contains 14 commonly endorsed barriers with a checkbox next to each item. Domains include logistical issues (e.g., forgetting, inconvenience), ingestion difficulties (e.g., swallowing, taste), efficacy (e.g., feel I don't need it), financial difficulties, regimen characteristics (e.g., too many medications, side effects), and patient-specific issues (e.g., refusal by child, embarrassment). A sum total of the number of barriers is calculated, as well as concordance between caregiver and patient report. In the feasibility study, the average concordance between caregiver and patient report of each barrier (n=48) was 0.299.53 The total barrier score will be used. A sum total of 0 to 14 could be calculated, with higher scores indicating more barriers.
| Number of Barriers | BMT4me 2.0 Intervention Group | BMT4me 2.0 Control Group |
|---|---|---|
| Enrollment (Week 0) | 4.24 ± 2.56 | 3.40 ± 1.80 |
| Exit (100 days post-transplant) | 2.34 ± 1.86 | 1.79 ± 1.61 |
Satisfaction will be assessed via semi-structured interviews and an electronic version of the Caregiver Satisfaction Questionnaire with caregivers. Caregivers will be asked for feedback regarding participation in the intervention, benefit, burden, barriers, suggested modifications, and overall satisfaction. Suggested modifications to the app and advice to the healthcare team will also be solicited. Due to the qualitative nature of the interview, caregiver responses cannot be scored but will be coded for themes. Nine questions are included on the Caregiver Satisfaction Questionnaire and responses are on a 1 to 4 Likert scale. A total sum score ranges from 9 to 36, with higher scores indicating more satisfaction.
| Scores on a scale | BMT4me 2.0 Intervention Group |
|---|---|
| Caregiver Satisfaction | 27.00 ± 4.19 |
Caregivers completed the Pediatric Quality of Life Inventory (PedsQL) every three weeks (at week 3, week 6, and week 9). The PedsQL has 4 domains related to physical, emotional, social, and school functioning totaling 23 items. Items are rated on a 3 or 5-point Likert scale. All items (23) are summed to a total PedsQL score. Total scores range from 0 - 100, with higher scores indicating higher quality of life. Versions are based on child age: (a) 5-7, (b) 8-12 and, (c) 13-18 years old.
| Scores on a scale | BMT4me 2.0 Intervention Group | BMT4me 2.0 Control Group |
|---|---|---|
| Week 3 | 73.85 ± 17.79 | 73.72 ± 14.76 |
| Week 6 | 76.58 ± 17.79 | 72.77 ± 18.67 |
| Week 9 | 77.56 ± 18.27 | 73.00 ± 20.44 |
Medy RPM collects daily data via an NFC reader. Each opening and closing is assumed to reflect an administered and consumed medication dose. This data will be collected monthly from participants as a direct measure of adherence. Electronic monitors contain micro-electronic circuits that date and time-stamp each time the container is opened to remove a dose of medication. Data from the electronic monitors will be downloaded using cloud or computer-based software, at each study visit. An adherence percentage was calculated by dividing the number of doses taken by the number of doses prescribed for each day. All of the electronic monitors have been independently tested for accuracy.
| Percent | BMT4me 2.0 Intervention Group | BMT4me 2.0 Control Group |
|---|---|---|
| Medy Remote Patient Management (RPM) Medication Box by Vaica | 69.34 ± 10.60 | 51.08 ± 8.45 |
Medication Level Variability Index (MLVI) measures the variation of tacrolimus levels in the blood of a patient over time. Higher variability has been associated with increased risk of poor outcomes following solid organ transplant, with limited findings suggesting a similar trend in HCT. MLVI is calculated using the standard deviation of three or more medication levels. The range of scores is not consistent, but MLVI typically falls between 0-10, with higher scores indicating higher variability (and therefore higher risk of complications). There are clinically significant cutoff scores for solid organ transplant populations; an MLVI of 3 or higher is generally considered to be a high risk. Both continuous and dichotomous scores were used in this analysis.
| Scores on a scale | BMT4me 2.0 Intervention Group | BMT4me 2.0 Control Group |
|---|---|---|
| Medication Level Variability Index (MLVI) | 3.87 ± 2.44 | 3.59 ± 1.66 |
GVHD will be assessed on the international standard acute GVHD grading and staging scale. Provider grading will be per organ system on a 1-4 scale, with an overall score given weekly.
| Participants | BMT4me 2.0 Intervention Group | BMT4me 2.0 Control Group |
|---|---|---|
| Number of Participants With Graft vs. Host Disease (GVHD) | 9 | 7 |
Readmission rates will be determined by the number of admissions requiring greater than a 24-hour stay within the first 100 days after discharge. Reason for readmission will be recorded and based on the EMR discharge diagnosis. In addition, a sub-analysis of readmissions within the first 30 days after initial discharge post-HSCT will be completed.
| Participants | BMT4me 2.0 Intervention Group | BMT4me 2.0 Control Group |
|---|---|---|
| Number of Participants With Readmissions | 9 | 11 |
Wisepill is a pillbox that collects data on medication usage through the internet. The Wisepill model utilized was evriMED1000. This data was collected as a direct measure of adherence. The evriMED1000 pillbox recorded when the lid was opened and closed and uploaded data in real time into a cloud-based server, where data was retrieved after study exit.
| Percent | BMT4me 2.0 Intervention Group | BMT4me 2.0 Control Group |
|---|---|---|
| Wisepill | 60.65 ± 26.27 | 60.52 ± 25.63 |
Caregiver reported education level
| Participants | BMT4me 2.0 Intervention Group | BMT4me 2.0 Control Group |
|---|---|---|
| Elementary | 1 | 0 |
| High School | 10 | 11 |
| Post-High School (Technical or Trade School) | 2 | 0 |
| College | 6 | 10 |
| Graduate/Professional | 4 | 5 |
| Missing | 1 | 0 |
Caregiver reported annual household income
| Participants | BMT4me 2.0 Intervention Group | BMT4me 2.0 Control Group |
|---|---|---|
| < $25,000 | 6 | 8 |
| $25,001 - $50,000 | 6 | 5 |
| $50,001 - $75,000 | 4 | 3 |
| $75,001 - $100,000 | 3 | 3 |
| $100,001 - $150,000 | 2 | 2 |
| > $150,001 | 1 | 3 |
| Missing | 2 | 2 |
Collected over Baseline (Week 0) to study exit (100 days posttransplant). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BMT4me 2.0 Intervention Group | 0/24 (0%) | 0/24 (0%) | 0/24 (0%) |
| BMT4me 2.0 Control Group | 0/26 (0%) | 0/26 (0%) | 0/26 (0%) |
| Age, Continuous(Years) | BMT4me 2.0 Intervention Group | BMT4me 2.0 Control Group | Total |
|---|---|---|---|
| Mean | 31.83 ± 10.48 | 35.19 ± 10.88 | 33.58 ± 10.71 |
| Sex: Female, Male(Participants) | BMT4me 2.0 Intervention Group | BMT4me 2.0 Control Group | Total |
|---|---|---|---|
| Female | 20 | 24 | 44 |
| Male | 4 | 2 | 6 |
| Race (NIH/OMB)(Participants) | BMT4me 2.0 Intervention Group | BMT4me 2.0 Control Group | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 4 | 6 |
| White | 19 | 19 | 38 |
| More than one race | 2 | 1 | 3 |
| Unknown or Not Reported | 1 | 2 | 3 |
| Ethnicity (NIH/OMB)(Participants) | BMT4me 2.0 Intervention Group | BMT4me 2.0 Control Group | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 2 |
| Not Hispanic or Latino | 20 | 24 | 44 |
| Unknown or Not Reported | 3 | 1 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2022 to primary completion in Jan 2026, 37 months.
Results were first posted in Oct 2026, 9 months after primary completion.
Of 429 non-industry interventional studies with no phase under Medication Adherence, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 42. This study's 37 months is above that.
Counting every sponsor, half of 447 studies reached it within 22 months; a quarter within 11 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Micah Skeens